Skip to main content
Clinical Trials/JPRN-UMIN000022603
JPRN-UMIN000022603
Completed
未知

on-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy. - Impact of evelocumab in homozygous familial hypercholesterolemia under LDL-apheresis.

Kanazawa University Hospital0 sites2 target enrollmentJune 4, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Homozygous familial hypercholesterolemia
Sponsor
Kanazawa University Hospital
Enrollment
2
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 4, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Myocardial infarction or unstable angina within 8 weeks Severe anemia (Hb \<10g/dL) Allergy against evolocumab Immunosupressive therapy Severe hepatic disorder (ASTorALT\>100IU/L) Severe renal disorder (BUN\>40mg/dL or Cre\>2\.0mg/dL) (Possible of) pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials